Table 2 Individual Demographics, Diagnosis, Treatment, and Outcomes of Osteomyelitis Patients Treated with Ertapenem
From: Ertapenem for treatment of osteomyelitis: a case series
Patient | Age (yrs) | Race | Gender | Comorbidities€ | Diagnosis¥ | Trauma-related | DiagnosticMethod | Surgical Intervention | No. Days on Erta | Other Antibiotic | Outcome at One Year£ |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 47 | White | Male | None | Recurrent chronic contiguous tibial osteomyelitis | Yes | Bone culture | Soft tissue debridement | 39 | None | F-Infection cleared at end of therapy, but recurred by one year |
2 | 56 | White | Female | COPD, DM, Pancreatic cancer | Initial chronic hematogenous vertebral osteomyelitis | Yes | Deep tissue culture | None | 39 | Suppressive moxifloxacin following ertapenem | F-Did not clear infection at end of therapy, but cleared by one year |
3 | 70 | White | Male | CAD, PVD | Initial chronic contiguous tibial osteomyelitis | Yes | Bone culture | Bone debridement | 33 | None | S-Infection cleared at end of therapy without recurrence at one year |
4 | 41 | White | Female | None | Initial acute contiguous toe osteomyelitis | Yes | MRI | None | 43 | Amoxicillin/clavulanate for 20 days preceding ertapenem | S-Infection cleared at end of therapy without recurrence at one year |
5 | 72 | White | Female | PVD, DM, CKD | Initial chronic contiguous toe osteomyelitis | Not known | MRI | None | 41 | See footnote1 Suppressive cephalexin following ertapenem | F- Did not clear infection at end of therapy, but cleared by one year |
6 | 64 | Black | Female | PVD, DM | Recurrent chronic contiguous malleolar osteomyelitis | Not known | MRI | None | 35 | Vancomycin and ampicillin/sulbactam for 6 days preceding ertapenem; suppressive ciprofloxacinclindamycin following ertapenem | F- Did not clear infection at end of therapy, but cleared by one year |
7 | 79 | White | Female | None | Initial chronic contiguous calcaneal ostemyelitis | No | Bone scan | None | 24 | None | S-Infection cleared at end of therapy without recurrence at one year |
8 | 76 | White | Female | Neurologic disease | Initial acute contiguous calcaneal osteomyelitis | No | MRI | Amputation | 26 | Imipenem for 14 days following therapy | S-Infection cleared at end of therapy without recurrence at one year |
9 | 47 | White | Female | DM | Initial chronic contiguous toe osteomyelitis | Not known | MRI | None | 42 | Piperacillin/tazobactam for 9 days prior to ertapenem | S-Infection cleared at end of therapy without recurrence at one year |
10 | 37 | White | Male | DM | Initial chronic contiguous toe osteomyelitis | No | MRI | None | 31 | Ampicillin/sulbactam for 3 days prior to ertapenem | S-Infection cleared at end of therapy without recurrence at one year |
11 | 48 | Black | Female | PVD, DM | Initial acute contiguous toe osteomyelitis | No | Plain film | None | 20 | Vancomycin for 4 days, piperacillin/tazobactam, 3 days, ceftriaxone for 2 days, all prior to ertapenem | F-Did not clear infection at end of therapy, nor by one year |
12 | 86 | Black | Male | CAD, PVD, DM | Initial chronic contiguous toe osteomyelitis | No | MRI | None | 42 | Piperacillin/tazobactam for 5 days prior to ertapenem | F- Did not clear infection at end of therapy, but cleared by one year |